Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis

Aiko Ogawa, Katsumasa Miyaji, Ichiro Yamadori, Yoko Shinno, Aya Miura, Kengo F. Kusano, Hiroshi Itoh, Hiroshi Date, Hiromi Matsubara

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are rare causes of pulmonary hypertension. There is no proven medical therapy to treat these diseases, and lung transplantation is thought to be the only cure. Administration of vasodilators including epoprostenol sometimes causes massive pulmonary edema and could be fatal in these patients. Methods and Results: Eight patients were treated with epoprostenol for 387.3±116.3 days (range, 102-1,063 days), who were finally diagnosed with PVOD or PCH by pathological examination. The maximum dose of epoprostenol given was 55.3±10.7 ng · kg -1 · min -1 (range, 21.0-110.5 ng · kg -1 · min -1). With careful management, epoprostenol therapy significantly improved the 6-min walk distance (97.5±39.2 to 329.4±34.6 m, P-1 · m -2 (P-1 · min -1. Conclusions: This study data suggest that cautious application of epoprostenol can be considered as a therapeutic option in patients with PVOD and PCH.

Original languageEnglish
Pages (from-to)1729-1736
Number of pages8
JournalCirculation Journal
Volume76
Issue number7
DOIs
Publication statusPublished - 2012

    Fingerprint

Keywords

  • Epoprostenol
  • Pulmonary capillary hemangiomatosis
  • Pulmonary hypertension
  • Pulmonary venoocclusive disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ogawa, A., Miyaji, K., Yamadori, I., Shinno, Y., Miura, A., Kusano, K. F., Itoh, H., Date, H., & Matsubara, H. (2012). Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Circulation Journal, 76(7), 1729-1736. https://doi.org/10.1253/circj.CJ-11-0973